---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-004708"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2026-07-16T11:31:17+00:00"
generated_at: "2026-07-16T11:35:11.867971+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Arbutus receives $178M from Moderna settlement, files patent suits against Pfizer/BioNTech, plans $230M share repurchase

## Summary
- Received approximately $178M from Moderna as its share of noncontingent settlement payment on July 8, 2026.
- Filed three international patent infringement lawsuits against Pfizer/BioNTech in Canada and UPC seeking injunctions and damages.
- Entered termination agreement with Genevant for RSV agreement, with Genevant paying $1.0M termination fee.
- Approved one-time cash bonuses for CEO Lindsay Androski (1.5% of $178M) and CFO Tuan Nguyen (0.25% of proceeds).
- Plans to return up to $230M to shareholders via share repurchases in Q3 2026 after receiving dividend from Genevant parent.

## SEC filing metadata
- accession: 0001171843-26-004708
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2026-07-16T11:31:17+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.02, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184326004708/0001171843-26-004708-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184326004708/f8k_071626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-004708
- JSON: https://secwatch.observer/filing/0001171843-26-004708.json
- Plain text: https://secwatch.observer/filing/0001171843-26-004708.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.